Manabu Nakamura

Director/Board Member at CHORDIA THERAPEUTICS INC.

58 year

Health Technology

Finance

Profile

Manabu Nakamura is currently Managing Partner & CEO at Shinsei Capital Partners Ltd since 2018, Director at Alphanavi Pharma KK, and Outside Director at Chordia Therapeutics, Inc. since 2024.
Formerly, Mr. Nakamura was Outside Director at Chordia Therapeutics, Inc. from 2019 to 2021.

Manabu Nakamura active positions

Companies	Position	Start
CHORDIA THERAPEUTICS INC.	Director/Board Member	2024-10-31
Shinsei Capital Partners Ltd Shinsei Capital Partners Ltd Investment ManagersFinance Shinsei Capital Partners is an active manager that provides financing for seed stage, early stage, later stage and pre-IPO stage capital requirements. The firm targets companies operating in the field of digital health and life sciences. It targets companies operating in Japan.	Chief Executive Officer	2017-12-31
Alphanavi Pharma KK Alphanavi Pharma KK Pharmaceuticals: MajorHealth Technology Manufactures drugs	Director/Board Member	-

All active positions of Manabu Nakamura

Former positions of Manabu Nakamura

Companies	Position	End
CHORDIA THERAPEUTICS INC.	Director/Board Member	2021-10-31

See the detail of Manabu Nakamura's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Manabu Nakamura's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
Chordia Therapeutics, Inc. Chordia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures oncology drugs	Health Technology
Alphanavi Pharma KK Alphanavi Pharma KK Pharmaceuticals: MajorHealth Technology Manufactures drugs	Health Technology
Shinsei Capital Partners Ltd Shinsei Capital Partners Ltd Investment ManagersFinance Shinsei Capital Partners is an active manager that provides financing for seed stage, early stage, later stage and pre-IPO stage capital requirements. The firm targets companies operating in the field of digital health and life sciences. It targets companies operating in Japan.	Finance